8-K

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                            ------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


        Date of Report (Date of Earliest Event Reported): April 22, 2003

                             POLYMEDICA CORPORATION
             ------------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

                                  Massachusetts
             ------------------------------------------------------
                 (State or Other Jurisdiction of Incorporation)


              0-19842                                    04-3033368
- --------------------------------------     -------------------------------------
     (Commission File Number)               (I.R.S. Employer Identification No.)

11 State Street, Woburn, Massachusetts                     01801
- --------------------------------------     -------------------------------------
(Address of Principal Executive Offices)                 (Zip Code)

                                 (781) 933-2020
                        --------------------------------
              (Registrant's Telephone Number, Including Area Code)

                        --------------------------------

                                       n/a
                        --------------------------------
          (Former name or former address, if changed since last report)



ITEM 9. REGULATION FD DISCLOSURE (INFORMATION FURNISHED PURSUANT TO ITEM 12,
        "DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION").

         On April 22, 2003, PolyMedica Corporation issued a press release with
respect to its expectations for fiscal 2004 first quarter earnings. The full
text of the press release is attached as Exhibit 99.1 to this Current Report on
Form 8-K.

         In accordance with the procedural guidance in SEC Release No. 33-8216,
the information in this Form 8-K and the Exhibit attached hereto is being
furnished under "Item 9. Regulation FD Disclosure" rather than under "Item 12.
Disclosure of Results of Operations and Financial Condition." The information
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing.






                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.



                                PolyMedica Corporation


Date:  April 24, 2003           By: /s/ John K.P. Stone III
                                    -----------------------------------------
                                    John K.P. Stone III
                                    Senior Vice President and General Counsel





                               INDEX TO EXHIBITS


Exhibit
Number          Description
- -------         -----------
99.1            Press release dated April 22, 2003

EX-99.1

[POLYMEDICA LOGO]



FOR IMMEDIATE RELEASE
- ---------------------

POLYMEDICA PROVIDES GUIDANCE FOR ITS FISCAL 2004 FIRST QUARTER ENDING JUNE 30TH

EXPECTS Q1 FY2004 NET REVENUES OF $97 - 100 MM; DILUTED EPS OF $0.84 - $0.90


WOBURN, MA, APRIL 22, 2003 - PolyMedica Corporation (NNM: PLMD) today announced
that for its fiscal 2004 first quarter ending June 30, 2003 the Company expects
to report net revenues of $97 - 100 million, compared to $81.6 million for the
same period last year. The Company also expects to report diluted earnings per
share of $0.84 - $0.90 for the fiscal 2004 first quarter.

Commenting on the Company's first quarter guidance, Samuel L. Shanaman, Lead
Director and Interim Chief Executive Officer, said, "Our business continues to
perform very well, in spite of the fact that extended television news coverage
on the war in Iraq has had some effect on the response to our TV ads early in
the quarter. It's important to remember that in a typical quarter, over
eighty-five percent of our revenues come from shipments to existing customers.
Our business model and the loyalty demonstrated by our customers continue to
provide a solid foundation for the consistent and predictable growth of our
business."

PolyMedica plans to announce financial results for its fourth quarter and fiscal
year ended March 31, 2003 during the week of May 26th. The Company remains
comfortable with its previously announced guidance for the fourth quarter of $94
- - 96 million in net revenues and $0.84 - $0.86 in diluted earnings per share.

ABOUT POLYMEDICA (WWW.polymedica.com)
PolyMedica is a rapidly growing national medical products and services company.
The Company is best known through its Liberty brand name and innovative
direct-to-consumer television advertising to seniors with diabetes and
respiratory disease. Building on its technology-based operating platform and
compliance management focus, PolyMedica continues to expand its product
offerings and services in these chronic disease and other categories.

This press release contains forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements are subject to risks and uncertainties, which could cause actual
results to differ materially from those anticipated. Such risks and
uncertainties include, but are not limited to, outcomes of government inquiries
and investigations and related litigation, continued compliance with government
regulations, unanticipated regulatory changes, changes in Medicare
reimbursement, fluctuations in customer demand, management of rapid growth,
intensity of competition from other healthcare product vendors, timing and
acceptance of new product introductions, general economic conditions,
geopolitical events and regulatory changes, as well as other especially relevant
risks detailed in the Company's filings with the Securities and Exchange




Commission, including its Annual Report on Form 10-K for the period ended March
31, 2002 and its Quarterly Report on Form 10-Q for the quarters ended June 30,
2002, September 30, 2002 and December 31, 2002. The information set forth herein
should be read in light of such risks. The Company assumes no obligation to
update the information contained in this press release.

                                      ###

FOR ADDITIONAL INFORMATION, CONTACT:

INVESTORS:                                  MEDIA:
Fred ("Skip") Croninger                     Denise DesChenes/Jim Barron
PolyMedica Corporation                      Citigate Sard Verbinnen
(781) 933-2020                              (212) 687-8080